Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mack/SS. Here is your info. Thanks Cabel, you are very valuable here because Leo has gained your trust.
Don’t drop the soap bro. Ur time is near and in Sullivan’s hands. What you post is pure bs
Precisely. I’d like to know more about the drop outs too.
Mack. I’ll get you answers in a bit. I have to go thru the criteria and time frames in the protocol. Remember all patients had the same protocol and time frames. CR treatment occurred for a specific amount of time IMO so the chart is very meaningful.
The reason the price is doing what it’s doing is because IPIX is EXTREMELY unknown. As it should be. There are 100’s upon 100’s of small public Bios.
This news is great for us that know IPIX. We all that believe in IPIX have already discussed the company and bright future with the people we know, and those people are invested already. So maybe, 1 or 2 of us come across a friend or colleague in a week that we bring up IPIX and so maybe we get a new investor here or there.
That is fine, because I’d rather have a natural KABOOM, than having someone like MOMO and his crew show up to pump this to 10 dollars just to have it crash.
Let’s see partner news with a BP. That BPs investors will then hear and learn about IPIX and we get global coverage and at that point very meaningful PRs that will increase SP. meaningful meaning SP increase
Jmo.
Aren’t your subscribers already all in? :)
Are you kidding? Honestly, by 4 year old nephew who does multiplication and speaks Spanish understands the graph Leo pointed out.
In his words, not mine: so around day 28-30 so many people got SOM in the placebo group. It spiked Uncle.
Wow, and so many taking B did not get SOM. Wow, so the onset of SOM had to wait another 2 full weeks for the fewer patients that got som rinsing with B! So uncle, how could they statistically come up with data to prove the duration of when getting Som if the B patients did not get it until so late?
Exactly son! I said. I’m going to make him pancakes now.
Great data!!!!
Happy New Year! Are you attending The Showcase? ;)
I expect the same here. No pump, real world pipeline at IPIX. And top class
Brilliant post. So simple.
Meat on this bone: “Meeting the primary endpoint of reduced incidence of SOM in this Phase 2 study was far more challenging than approaches taken for other drugs in development for this notoriously difficult indication. This feature of Brilacidin-OM greatly differentiates it from other experimental drugs that only address time to onset and duration of SOM. The Company believes our clinical results provide a clear path for expedient development and eventual marketing, which would represent the first drug of its kind to garner FDA approval. These study results position the Company as a global leader in developing a drug to prevent the onset of SOM. Management believes that the Company’s market capitalization has not yet reflected the value created by this accomplishment given the fact that there are no competing treatments in an untapped and enormous market. One need only speak with a radiation oncologist to realize the great need to protect against SOM of any origin and the potential sales for such a drug. Recent analyst reports estimate the global OM market at $1-2 billion per year. “
I hope so. I have never heard Leo say they plan on attending the JP Morgan Show in the past. Maybe we have new friends!
Maybe a chance for secondary data sets as Leo suggested more data will be released I think in intervals for OM as the get it, so maybe we get duration times? But I don’t expect much. I did enjoy the PR stating they are not only presenting at the biotech but also attending the big boy one across the street. They never told us that before.....
He’s saying that because of the 8th. Their will be a presentation which IMO will simply disclose what we already know. So news...yes.
IMO!!! Happy New Year
I'll guess we skip 2 and hit 6 and much higher first. Mega deal in the works!
Maybe the data released this week helps BP jump in
Partner for K could be huge for expediting all the different tests on different cancers and combos, etc... we need a bite from a BP that has a successful OC drug...let’s see where combo can get us and this world!
Agree. And IPIX brought us to a place where we can have a partner for 3 drugs and 5 indications at any time.
We just need competition. The more BPs interested the quicker term sheets are delivered. However, maybe they already know their suitor....we will find out.
Interesting thought. There are so many ways this can go...it will be exciting to see which drug and indication is our first to partner.
Mgmt is correct, it will transform this company overnight!
K results this week were just another DEEeee-RISK event. The market is not even watching. Currently
Here is what’s coming: a mega deal!
The stars could not align more perfectly...imo. With the new legislation, the way IPIX has brought so many drugs to late stage trials while leaving all the imagination untouched so far is brilliant.
We all are going to see a deal that is far above all expectations. To bad for your BP.
So true. Great post. The facts are, this company has a potential that is unfathomable and there are many here by reading posts that are working hard to spread lies and trying to derail what could be worth 10,s of billionS.
This part: “...actively engaging global and regional pharmaceutical companies interested in licensing our novel drug candidates.”
So now we know, licensing is the goal
I think we see a partner soon. Too much to do and learn on our own for K. IMO.
No no. It’s all been discussed here. Leo has zero skeletons. We’ve actually discussed his past in person and there is nothing illegal or anything to hide.
The man has been nothing short of spectacular here.
Slow clap. Thanks
PREVENTION is the key word again:
Importantly, these data directly support Kevetrin's ability, in ovarian cancer patient tumors, to affect p53 and associated molecular pathways -- the central gene signaling network involved in regulating cell growth and the cell cycle, helping to prevent cancer.
The full data will be intriguing. Especially after these patients take K for 3 weeks and then standard of care right after to see if K set the stage for better results from SoC. So many possibilities, and unknowns in cancer research....but step 2 after safety was to CONFIRM MoA and BOOM! Observation was confirmed.
In oncology....this is really good news. IMO.
I’m going off the grid for a meeting but can’t wait to see what the lemmings say about this.
Going to a meeting myself...I’ll try and look at criteria when I get a second.
This PR means a lot to me. So many idiots here posted K is done. This my friend screams the opposite......its just getting started. Which BP owns the Ovarian space? Combo therapy is where this is going to FLY!!!! Imo
This may help recruit too!
Innovation Pharmaceuticals Obtains Direct Evidence of Molecular Pathways Modulation in Tumors from First Patients in Kevetrin Ph2a Ovarian Cancer Trial
BEVERLY, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce highly encouraging preliminary data from the first patients treated in the Company’s Phase 2a clinical trial (see NCT03042702) of Kevetrin for ovarian cancer.
Modulation of the p53 protein was observed in response to administration of Kevetrin. Pathways analyses also point to concomitant cell cycle modulation at the level of gene expression. Importantly, these data are the first to directly support in ovarian cancer patient tumors, Kevetrin’s ability to affect p53 and associated molecular pathways—a central gene signaling network involved in regulating cell growth and the cell cycle, helping to prevent cancer.
In more detail, preliminary analyses used Western Blots to assess relative levels of key proteins extracted from tumor biopsies before and after a series of nine Kevetrin infusions administered over three weeks. The level of phospho-p53, the activated form of the protein, in addition to the noted p53 modulation, was also seen to change in response to Kevetrin administration. These findings confirm in patient tumors Kevetrin-induced anti-cancer effects similar to those demonstrated (pdf) preclinically in ovarian cancer cell-lines. These new data reinforce prior clinical data, from the earlier concluded Phase 1 study of Kevetrin in advanced solid tumors (see NCT01664000), in which observations of p21 expression in peripheral blood monocytes supported p53 involvement in Kevetrin’s mechanism of action.
Data from RNAseq analyses of expressed mRNAs and sRNAs in tumors, before and after treatment with Kevetrin, are being further analyzed to assess the nature and scope of molecular pathways modulations. The strongest signal so far detected concerns the cell cycle and a variety of transcription factors.
Running in parallel, the Company is making plans to develop Kevetrin as an oral agent (tablet or capsule) that could be dosed multiple times per day, leveraging its short half-life and pharmacokinetic profile. Bioavailability and other lab studies have been encouraging. Last, linked below is a blog post, published on the Company’s website, further elaborating on Kevetrin’s treatment potential as a novel, p53-modulating anti-cancer drug candidate.
“Kevetrin’s Effect on the p53 Signaling Pathway in a Broader Scientific Context”
Management Comments
“In a majority of cancers, p53 is mutated, preventing the body from performing its anti-tumor functions,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “As a result, therapies targeting p53 have long been pursued, highly sought-after by Big Pharma, but have largely been met with limited success due to the inherent complexity of p53. So, to see Kevetrin modulate p53 in a clinical setting, in tumor biopsies from patients, is an exciting moment for the Company and positioning us at the forefront of developing a potentially transformative anti-cancer therapy.”
“Our science team has been working on Kevetrin for over a decade now, studying its unique anti-cancer profile across multiple cancer types, from solid tumors to leukemias—a function of Kevetrin’s ability to induce apoptosis in both wild type p53 and mutant p53 tumors,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “It’s rewarding to think—after so many years of research in the lab and in the clinical setting—that we now have more direct evidence of how Kevetrin’s multiple mechanisms of action modulate p53, helping to restore the body’s natural ability to fight cancer. Such mechanistic insights of the kind we’re observing will prove invaluable as we continue to advance Kevetrin into later-stage clinical development.”
Yes!!!!!!!! This is one of the most rewarding PRs in my 6 year investment!!!
This is so important for cancer therapy.
Excellent question! One that Sullivan surely knows by now.
Don’t drop the soap six
And that 60 should be 70-80....a freak placebo event on this trial looking at all previous OM trials.
Agree. Once we can rip away from this audience and lose the little retail penny traders we will be on our way.
I'm just excited to see what unfolds, because there are legitimately dozens of ways this first deal can unfold......especially when thinking about Brilacidin.
Secondary data could in fact set these young kids straight. It will be interesting.
That's what I was saying about the picture in my last post. It's not real. I love the fact that if you read this board, you would almost conclude IPIX only has one last hope to survive! And that last ditch effort is a mediocre B-OM. Lol!!!!! I mean....you would think that K does not exist and was a failure. You would think b absssi is just a mirage and fake. Prurisol did nothing in phase 2a. That's the picture being painted here.
It's not even close to the facts. Not even 1% true.
Kevetrin was safe. One of the first if not the first safe p53 drug. A patient had their tumors disappear. Read the patient reports: more energy, felt better, etc!!! People going on walks or hikes...enjoying life!!! Is there an issue with a short half-life? Yes, but they are working on Oral K....and so far so good!
I can go on about Prurisol and others but it doesn't matter here, the picture is being painted and will continue to be a false image here.
New investors need to do their own DD. Watch the next presentation to get the real facts on January 8th.
Go to a conference and be open minded. There is one in January. Listen when you speak to management. They will have the utmost confidence when speaking about the pipeline. This world here in online messaging is not real. This is a picture that someone is painting. Nothing said here is real, I'm not real for all you know. Why do you love the company one minute and then turn negative the next? Why do dozens of posters do the same? Why are their people just saying FUD here day in and day out? It's all imaginary! The real deal is speaking to management and reading the sec documents and PRs and blogs by the company. If you follow those ...that's the real story in the real world.
"If necessary" IPIX could do a dozen things if needed. However, there is absolutely no need to do anything. The plan is playing out better than expected if you speak to people close to mgmt. have they diluted on shareholders? Yes, but 45 million over 6 years for 8 successful human trials including purchasing poly assets and hiring top execs is literally nothing. I've seen 100s of millions and reverse splits for 1 or two trials.
I agree with you, IPIX could sell absssi for cheap if they wanted...but there is no need. Huge OM deal coming soon. And P may blow us all away.
P manufacturing is gold! P patents are gold. P is fully owned by IPIX and does not need to share any profits. If it matches Otezla we are all set for life. IMO. 3-5 years additional exclusive rights will be granted due to 505 2b. That alone is worth billions if it matches Otezla. IMO.
Merry xmas